In case you are diagnosed with VTE.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=171777&CultureCode=en
University of Leicester involved in study into cholesterol-lowering pill
Statins could hold the key to eradicating one of the most preventable
causes of hospital deaths after researchers uncovered a new role for
the cholesterol-lowering pill.
The medication, commonly used to prevent heart attacks, reduces the
threat of a condition affecting millions globally called venous
thromboembolism (VTE), where blood clots form in the vein in the lungs
or in limbs, by between 15 and 25 per cent.
The conclusion was made following a thorough analysis of 36 studies
involving more than 3.2 million people as part of new research published
in The Lancet Haematology. It was supported by NIHR Collaboration for
Leadership for Applied Health Research and Care (CLAHRC) East Midlands
and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical
Activity Biomedical Research Unit.
The results of the summary compiled by researchers from Leicester
Diabetes Centre and the University of Bristol provide an “extensive body
of evidence on the clinical benefit of statin in the occurrence of
VTE”.
The finding could potentially lead to new guidelines and an expansion
of the use of treatment, which is already established in cardiovascular
disease prevention.
Co-investigator Professor Kamlesh Khunti, Professor of Primary Care
Diabetes & Vascular Medicine at the University of Leicester,
Director NIHR CLAHRC East Midlands and Co-Director of the Leicester
Diabetes Centre, said: “These findings underscore a potential beneficial
role of statin therapy on VTE in addition to its established role in
cardiovascular disease prevention.”
Lead researcher Dr Setor Kunutsor, from the University of Bristol’s
Musculoskeletal Research Unit, added: “Currently, statins are only
approved for lipid lowering in the primary and secondary prevention of
cardiovascular disease.
“But they have shown great promise beyond their established
lipid-lowering effects and these include potential beneficial impact on
multiple disease conditions.
“These results provide an extensive body of evidence on the clinical
benefit of statin in the occurrence of VTE and may support a true
protective effect.”
NIHR CLAHRC East Midlands is a collaboration of NHS, universities,
patients and industry turning research into cost-saving and high-quality
care through cutting-edge innovation.
The Leicester Diabetes Centre, based at Leicester General Hospital,
is an international centre of excellence in diabetes research and
education. It is a partnership between the University Hospitals of
Leicester NHS Trust and the University of Leicester led by Professor
Khunti and Professor Melanie Davies CBE.
http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(16)30184-3/fulltext
No comments:
Post a Comment